The content on this site is intended for healthcare professionals only
Prof John Allan speaks to ecancer in an online interview for the EHA 2021 virtual meeting about the primary analysis of the CAPTIVATE study.
He explains that the phase II study looked at first-line ibrutinib plus venetoclax for chronic lymphocytic leukaemia / small lymphocytic lymphoma, and focuses on talking about the fixed-duration cohort. He notes that this is an all-oral, once-daily, chemotherapy-free regimen.
Prof Allan reports that this treatment showed favourable, safe and effective results in this patient cohort, and says that this is promising for opening up a new treatment option for these patients.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
EHA 2024: Multiple myeloma roundup
Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line
More effective treatment options required for patients with MM post lenalidomide exposure
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
